基因治疗的“3Y”问题与原则  

3Y" Problem and Principle in Gene Therapy

作　　者：胡春松[1] 

机构地区：[1]江西医学院心血管病研究所,南昌330006

出　　处：《遗传》2003年第5期577-580,共4页Hereditas（Beijing)

基　　金：国家留学基金委(www.csc.edu.cn)1998年度(No.98836007)资助

摘　　要：以病毒和非病毒为载体的体细胞基因治疗是一种富有前景的治疗人类疾病的方法。然而,当前人类疾病基因治疗应用的限制主要是转基因方法的潜在风险、相对低效率和靶基因的胞内稳定性。因此,我们总结其为基因治疗的"3Y"问题———安全性(safety)、有效性(efficacy)和稳定性(stability),并认为这也是人们应遵守的基因治疗的"3Y"原则。Somatic gene therapy based on nonviral and viral vectors is an attractive approach for treatment of human diseases.However,the application of gene therapy to human disease is currently hampered by potential hazards of methods of gene delivery,the relatively low efficiency and intracellular stability of target gene.Therefore,we summarized them as the '3Y' problems--(safety,efficacy and stability) and also think people should abide the '3Y' principles in gene therapy.

关 键 词：基因治疗 载体 靶基因 安全性 有效性 稳定性 

分 类 号：R456[医药卫生—治疗学] R394[医药卫生—临床医学]